121 results on '"van Balen, Peter"'
Search Results
2. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses
3. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens
4. The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide.
5. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation
6. Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM
7. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data
8. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation:Dutch real-world data
9. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data
10. Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning
11. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion
12. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation—a phase I/II study
13. Joint models quantify associations between immune cell kinetics and allo-immunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion
14. Asbest in straalgrit: Een idee over de blootstelling is het begin en het einde
15. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
16. Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS
17. Mapping AML heterogeneity – multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses
18. Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning
19. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population
20. Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population
21. Joint models quantify associations between immune cell kinetics and alloimmunological events after allogeneic stem cell transplantation and subsequent donor lymphocyte infusion.
22. Single cell guided deconvolution of bulk transcriptomics recapitulates differentiation stages of acute myeloid leukemia and predicts drug response
23. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion
24. Human T cells recognize HLA-DP–bound peptides in two orientations
25. Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
26. Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation
27. Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
28. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response
29. Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation
30. Promiscuity of Peptides Presented in HLA-DP Molecules from Different Immunogenicity Groups Is Associated With T-Cell Cross-Reactivity
31. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study
32. Immunopeptidome Analysis of HLA-DPB1 Allelic Variants Reveals New Functional Hierarchies
33. HLA-DM Mediates Permissiveness of HLA-DPB1 T Cell Epitope Mismatches in Unrelated HCT
34. 150 PDC on workplace air exposure assessment using freeware apps Part I: Basic characterisation and measurement processing
35. Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation—a phase I/II study
36. Asbest in straalgrit
37. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II
38. Dissecting Genetic Control of HLA-DPB1 Expression and Its Relation to Structural Mismatch Models in Hematopoietic Stem Cell Transplantation
39. The allogeneic HLA-DP-restricted T-cell repertoire provoked by allogeneic dendritic cells contains T cells that show restricted recognition of hematopoietic cells including primary malignant cells
40. Tissue Damage Caused by Myeloablative, but Not Non-Myeloablative, Conditioning before Allogeneic Stem Cell Transplantation Results in Dermal Macrophage Recruitment without Active T-Cell Interaction
41. Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing
42. Letters to the Editor
43. Alloreactivity to HLA-DP is modulated by selft-cell epitopes in the responder
44. Randomized Trial of Prophylactic Donor Lymphocyte Infusion with Positively Selected CD4+ T Cells after HLA-Identical Allogeneic Stem Cell Transplantation
45. A Dutch Family with Hb Debrousse: Severe Anemia After Parvovirus B19 Infection
46. Prognosis Following Severe Head Injury: Development and Validation of a Model for Prediction of Death, Disability, and Functional Recovery
47. Undetectable HDL-cholesterol due to the presence of paraproteinemia
48. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
49. [Work-related asthma in clinical practice].
50. B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.